Flag of the European Union EU Clinical Trials Register Help

Clinical trials for FOLFOX

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    123 result(s) found for: FOLFOX. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2005-003443-31 Sponsor Protocol Number: D8480C00041 Start Date*: 2006-04-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination...
    Medical condition: Metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) CZ (Completed) ES (Completed) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003440-66 Sponsor Protocol Number: D8480C00013 Start Date*: 2006-09-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizuma...
    Medical condition: This is a Phase II / III trial in Patients with Previously Untreated Metastatic Colorectal Cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) CZ (Completed) DE (Completed) SK (Completed) HU (Completed) IT (Completed) GB (Completed) FI (Completed) LV (Completed) MT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002987-84 Sponsor Protocol Number: A6181104 Start Date*: 2008-07-31
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US
    Full Title: A RANDOMIZED, PHASE 2B STUDY OF SUNITINIB PLUS OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFOX) VERSUS BEVACIZUMAB PLUS FOLFOX AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Medical condition: METASTATIC COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-014593-18 Sponsor Protocol Number: CT-2008-01 Start Date*: 2009-12-07
    Sponsor Name:CureTech
    Full Title: CT-2008-01: Phase II study to evaluate the safety, tolerability and efficacy of FOLFOX + CT-011 versus FOLFOX alone administered intravenously to patients with colorectal adenocarcinoma previously ...
    Medical condition: This study will enroll patients with untreated, metastatic colorectal carcinoma who are eligible for first line FOLFOX therapy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008282-36 Sponsor Protocol Number: GPICD–CR–0801 Start Date*: 2010-05-07
    Sponsor Name:Grupo de Investigação do Cancro Digestivo
    Full Title: Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line...
    Medical condition: Colorectal cancer KRAS wild-type
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001194-14 Sponsor Protocol Number: D8480C00051 Start Date*: 2006-10-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of AZD2171 when added to 5 fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) w...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019564-37 Sponsor Protocol Number: GMIHO-010/2009 Start Date*: 2011-05-02
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH
    Full Title: A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects with Metastatic Colorectal Carcinoma Receiving Panitumumab
    Medical condition: Skin toxicity treatment in patients with wild-type KRAS metastatic colorectal cancer (mCRC) treated with panitumumab • In first-line in combination with FOLFOX • In second-line in combination wit...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000974-44 Sponsor Protocol Number: D910CC00001 Start Date*: 2019-10-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer ...
    Medical condition: Metastatic Microsatellite-Stable Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004706-14 Sponsor Protocol Number: MT201-204 Start Date*: 2009-02-09
    Sponsor Name:Micromet AG
    Full Title: A randomized, open-label, controlled, multi-center Phase II study to evaluate the efficacy and safety of adecatumumab alone or sequentially to FOLFOX relative to FOLFOX after R0 resection of colore...
    Medical condition: R0 resected liver metastases from colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004166-18 Sponsor Protocol Number: FFCD1201 Start Date*: 2013-01-09
    Sponsor Name:Fédération Francophone de Cancérologie Digestive (FFCD)
    Full Title: Intra-arterial hepatic beads loaded with irinotecan (Debiri) with concomitant chemotherapy with FOLFOX in patients with colorectal cancer with unresectable liver metastases: a phase II multicenter ...
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003858-33 Sponsor Protocol Number: AM0010-301 Start Date*: 2017-05-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi...
    Medical condition: Advanced Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006283-30 Sponsor Protocol Number: A4061034 Start Date*: 2008-02-13
    Sponsor Name:Pfizer, S.A.
    Full Title: Estudio aleatorizado en fase 2 de Folfox o Folfiri con AG-013736 o Bevacizumab en pacientes con cáncer colorrectal metastásico después del fracaso a una pauta de primera línea con irinotecan u oxal...
    Medical condition: Segunda linea de tratamiento en pacientes con carcinoma colorectal. Second line treatment of patients with metastatic carcinoma of colon and rectum
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    9.1 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) FR (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005022-23 Sponsor Protocol Number: D4200C00047 Start Date*: 2007-03-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-Blind, Placebo Controlled, Randomised Study To Assess The Efficacy And Safety Of 2 Doses Of ZACTIMA (ZD6474) In Combination With FOLFOX vs FOLFOX Alone For The Treatment Of Color...
    Medical condition: Colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003740-77 Sponsor Protocol Number: PERFU_001 Start Date*: 2019-12-09
    Sponsor Name:Amsterdam UMC location VUmc
    Full Title: Personalized prediction and regulation of 5-FU exposure
    Medical condition: The clinical trial is conducted in patients undergoing FOLFOX, FOLFIRI and FOLFIRINOX chemotherapy. Most of these patients have colorectal or pancreatic cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003306-13 Sponsor Protocol Number: CCR4557 Start Date*: 2017-05-16
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: CCR 4557: Peri-operative Immuno-Chemotherapy in Operable oesophageal aNd gastrIc Cancer (ICONIC Trial)
    Medical condition: Operable oesophageal and gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000698-22 Sponsor Protocol Number: MK-7339-003 Start Date*: 2020-02-26
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with a Fluoropyrimidine in Participants with ...
    Medical condition: The treatment of participants with unresectable or metastatic CRC that has not progressed following an induction course of FOLFOX + bevacizumab
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) FR (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-006766-28 Sponsor Protocol Number: TTD-08-04 Start Date*: 2009-02-04
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos - TTD
    Full Title: Estudio de fase II exploratorio, abierto, aleatorizado, multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con quimioterapia FOLFOX 4 o panitumumab con quimioterapi...
    Medical condition: Pacientes con cáncer colorrectal con KRAS no mutado y metástasis sólo hepáticas.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011445-13 Sponsor Protocol Number: IJB-BGDO-2009-001 Start Date*: 2009-11-26
    Sponsor Name:Institut Jules Bordet-Université Libre de Bruxelles
    Full Title: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer
    Medical condition: Stage III colon adenocarcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004112-19 Sponsor Protocol Number: POLARIS2013-001 Start Date*: 2018-07-10
    Sponsor Name:Polaris Pharmaceuticals, Inc.
    Full Title: Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma
    Medical condition: Advanced hepatocellular carcinoma (HCC)in the third line or later setting
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011899-30 Sponsor Protocol Number: 20080259 Start Date*: 2009-12-18
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizum...
    Medical condition: Locally-advanced or Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) CZ (Completed) BE (Completed) IE (Completed) IT (Completed) FR (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 15:42:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA